When bad news drops, investors have a tendency to sell first and ask questions later. Let's take a closer look at why Viking ...

Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra ...

Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...

In April 2025 , Northstrive Biosciences announced it received preliminary feedback from the FDA on its planned Type B pre-IND ...